303-16-2

Basic information

• Product Name: 2-(2,5-Dioxopyrrolidine-3-yl)-1H-isoindole-1,3(2H)-dione
• Synonyms: 2-(2,5-Dioxopyrrolidine-3-yl)-1H-isoindole-1,3(2H)-dione;3151IS;3-Phthalimidylpyrrolidine-2,5-dione;EM-20;N-(2,5-Dioxo-3-pyrrolidinyl)phthalimide;1H-Isoindole-1,3(2H)-dione, 2-(2,5-dioxo-3-pyrrolidinyl)- (9ci);2-Ftalimmidosuccinimide;2-Ftalimmidosuccinimide [italian]
• CAS NO: 303-16-2
• Molecular Formula: C₁₂H₈N₂O₄
• Molecular Weight: 244.2029
• Mol File: 303-16-2.mol

Chemical Properties

• Boiling Point: 500.9°Cat760mmHg
• Flash Point: 256.7°C
• Appearance: /
• Density: 1.585g/cm³
• Vapor Pressure: 3.65E-10mmHg at 25°C
• Refractive Index: 1.673
• CAS DataBase Reference: 2-(2,5-Dioxopyrrolidine-3-yl)-1H-isoindole-1,3(2H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2,5-Dioxopyrrolidine-3-yl)-1H-isoindole-1,3(2H)-dione(303-16-2)
• EPA Substance Registry System: 2-(2,5-Dioxopyrrolidine-3-yl)-1H-isoindole-1,3(2H)-dione(303-16-2)

Safety Data

• Hazardous Substances Data: 303-16-2(Hazardous Substances Data)

Usage

Molecular structure

Heterocyclic compound with a complex structure, containing both pyrrolidine and isoindole rings.

Molecular weight

267.24 g/mol

Functional groups

Contains pyrrolidine, isoindole, and dione functional groups.

Potential applications

May have use in pharmaceuticals, organic synthesis, and material science.

Research status

Further research and study needed to fully understand its properties and potential uses.

InChI:InChI=1/C12H8N2O4/c15-9-5-8(10(16)13-9)14-11(17)6-3-1-2-4-7(6)12(14)18/h1-4,8H,5H2,(H,13,15,16)

Upstream product

• 85-44-9 phthalic anhydride 
• 5615-80-5 L-3-aminosuccinimide 

Relevant articles and documents

NEW CRBN MODULATORS

Disclosed are degraders, pharmaceutical compositions containing them, and methods of making and using the degraders to treat diseases and disorders characterized by dysregulated or dysfunctional protein activity that can be targeted by cereblon.

REGULATING CHIMERIC ANTIGEN RECEPTORS

This invention is in the area of compositions and methods for regulating chimeric antigen receptor immune effector cell, for example T-cell (CAR-T), therapy to modulate associated adverse inflammatory responses, for example, cytokine release syndrome and tumor lysis syndrome, using targeted protein degradation.

TUNABLE ENDOGENOUS PROTEIN DEGRADATION WITH HETEROBIFUNCTIONAL COMPOUNDS

The present invention provides a means to modulate gene expression in vivo in a manner that avoids problems associated with CRISPR endogenous protein knock-out or knock-in strategies and strategies that provide for correction, or alteration, of single nucleotides. The invention includes inserting into the genome a nucleotide encoding a heterobifunctional compound targeting protein (dTAG) in-frame with the nucleotide sequence of a gene encoding an endogenously expressed protein of interest which, upon expression, produces an endogenous protein-dTAG hybrid protein. This allows for targeted protein degradation of the dTAG and the fused endogenous protein using a heterobifunctional compound.

SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION

Disclosed are small molecules against cereblon to enhance effector T cell function. Methodos of making thes molecules and methods of using them to treat various disease states are also disclosed.